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Abstract
Multiple myeloma is a common hematologic malignancy that is associated with reduced 
cellular as well as humoral immunity ultimately causing various infectious complications. 
The recent advances in the management of myeloma have led not only to prolonged sur-
vival but also to shifts in the incidence as well as the spectrum of infections encountered. 
This book chapter will be an updated review on the infectious complications in patients 
with multiple myeloma in the era of novel agents, stem cell therapies, and monoclonal 
antibodies. It will cover causes of immunosuppression, timing, and types as well as man-
agement of the various infections reported with various therapeutic modalities that are 
currently utilized in the management of myeloma patients.
Keywords: multiple myeloma, hematopoietic stem cell transplantation, novel therapies, 
monoclonal antibodies, infectious complications
1. Introduction to multiple myeloma
Multiple myeloma (MM), the second most common hematologic malignancy (HM), is a plasma 
cell neoplasm characterized by production of a monoclonal immunoglobulin that ultimately 
leads to several complications including anemia, renal dysfunction, bone disease, immunode-
ficiency, and various infections [1–5].
Over the past two decades, the outcomes of patients with MM have improved substantially 
due to the following: (1) the widespread utilization of high-dose (HD) chemotherapy fol-
lowed by autologous stem cell transplantation (HSCT), (2) the introduction of several novel 
therapies and monoclonal antibodies, (3) the evolution of advanced technology that facilitated 
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understanding of the biology of the disease and helped in the diagnosis, risk stratification 
and follow-up of patients, (4) the evolution of new therapeutic strategies such as consolida-
tion and maintenance treatments as well as total and continuous therapy, and (5) improve-
ments in supportive care and antimicrobial therapies [1, 3–12]. Currently, the following novel 
therapies are available for patients with MM: (1) immunomodulatory agents such as tha-
lidomide, lenalidomide, and pomalidomide; (2) proteasome inhibitors such as bortezomib, 
carfilzomib, and ixazomib; (3) monoclonal antibodies such as daratumumab and elotuzumab; 
and (4) histone deacetylase inhibitors such as panobinostat and vorinostat [1, 3, 4, 6, 9, 11]. 
Unfortunately, despite the remarkable progress achieved in the diagnostics and therapeutics 
and the plethora of therapeutic modalities, MM remains incurable [1, 4, 5, 7, 11]. The numer-
ous treatment modalities that are available for patients with MM have shown their effective-
ness, but they have their own adverse effects including bone marrow (BM) suppression and 
infectious complications that may be life-threatening [13–15].
The standard induction therapy in patients with newly diagnosed MM is the triplet regimen 
of bortezomib, lenalidomide, and dexamethasone [4, 16]. Autologous HSCT is the standard of 
care for transplant-eligible patients either upfront or at relapse [4, 10, 16]. Studies have shown 
that post-HSCT consolidation and maintenance treatments can further improve the outcome 
of patients with MM [10, 16, 17]. Monitoring disease response at various stages of treatment 
is essential and studies have shown that monitoring of minimal residual disease is associated 
with longer progression-free survival (PFS) and overall survival (OS) [18, 19].
2. Early mortality in MM
In patients with MM, several studies have shown that risk factors for early mortality include 
male gender, age >75 years, poor performance status, presence of comorbid medical condi-
tions such as renal failure and hypertension, low platelet count, low serum albumin level, 
elevated serum levels of calcium and lactic dehydrogenase, low body mass index, presenta-
tion with primary plasma cell leukemia, advanced stage of disease at presentation, and infec-
tious complications [20–25]. Two major studies that included 451 and 299 patients with MM 
showed that 65 and 45% of early deaths were attributable to infections [20, 21].
Despite the use of prophylactic antimicrobials, infections remain a leading cause of mortality 
and morbidity in patients with MM [26]. In patients with MM, approximately 45% of deaths 
occurring within 60 days of diagnosis are caused by various infections, predominantly pneu-
monia and sepsis [20, 26].
3. Reduced immunity in patients with MM
In patients with MM, causes of immunosuppression include: (1) the immunosuppressive 
effects of the disease or the direct immunosuppression caused by tumor cells, particularly 
in advanced stage or refractory disease, (2) therapeutic interventions to control MM, such 
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as corticosteroids, cytotoxic chemotherapy, and the novel therapies such as thalidomide, 
lenalidomide and bortezomib reduce the immunity further by different mechanisms includ-
ing neutropenia and mucositis, (3) old age and its immunosuppressive effects, (4) impairment 
of the capacity of the immune system to mount effective responses or challenges to infec-
tion or vaccination, (5) further suppression of the immune system by the administration of 
HD chemotherapy (melphalan) followed by autologous HSCT, and (6) presence of comorbid 
medical conditions [14, 27–31].
In patients with MM, the risks of infectious complications and disease progression are 
enhanced by following forms of dysfunction of the immune system: reduced antigen pre-
sentation, high cytokine levels and increased suppressive cells such as CD8 Tregs [32, 33]. 
Both cellular and humoral components of the immune system are suppressed in patients with 
MM [28, 34, 35]. Hypogammaglobulinemia or immunoparesis is associated with unfavor-
able prognosis in newly diagnosed patients with MM [34]. In a Danish study that included 
2558 patients with MM, immunoparesis at diagnosis was not confirmed to be an independent 
prognostic factor for OS, but quantitative immunoparesis was found to be associated with a 
shorter PFS [34].
Patients with MM have increased susceptibility to infections due to the profound B-cell dys-
function or the depression in humoral immunity [36]. These patients are 10 times more prone 
to infections than patients with Waldenstrom’s macroglobulinemia and 5 times more prone 
to infections than individuals with monoclonal gammopathy of undetermined significance 
[36]. MM patients have increased susceptibility to severe pneumococcal infections, and they 
respond poorly to pneumococcal vaccination [35, 36].
The highest risk of infection occurs within the first month after the diagnosis of MM, particu-
larly in patients with renal failure [14, 36]. The infections that are encountered in patients with 
MM include urinary tract infection, pneumonia, septicemia, fungal infections, and viral infec-
tions such as influenza virus and varicella zoster virus (VZV) infections [14, 36]. However, bacte-
rial infections predominate particularly those caused by: Staphylococcus aureus, Streptococcus 
pneumonia, Haemophilus influenzae, and Escherichia coli [14, 36]. The advent of autologous HSCT 
and the introduction of novel therapies in patients with MM have led to a shift in the spectrum 
of infections with increased incidence of viral and fungal infections [13, 36]. In a recent study, 
mitogen stimulation of cytokine release profiling for interleukin (IL)-5, IL-13, Th1, and Th2 
was used to predict the risk of infections in patients with MM during maintenance therapy, 
but only IL-5 response was found to be predictive of infection on multivariate analysis [37].
4. Infectious complications in MM
The risk factors for infectious complications in patients with MM can be divided into patient-
related factors, disease-related factors, and treatment-related factors as shown in Table 1 [13, 
14, 38–45]. However, the infections encountered in patients with MM include: (1) bacterial 
infections, predominantly involving respiratory and urinary tract, caused by Streptococcus 
pneumonia, Staphylococcus aureus, Haemophilus influenzae, Klebsiella pneumonia, Escherichia coli, 
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Pseudomonas aeruginosa, and Enterobacteriaceae; (2) viral infections caused by herpes simplex 
virus (HSV), VZV, and cytomegalovirus (CMV); (3) fungal infections caused by Candida species 
and Aspergillus species; and (4) Pneumocystis jiroveci pneumonia (PJP) [14, 43, 44, 46–48].
The sites of infections in patients with MM include: (1) upper and lower respiratory tract with 
otitis, sinusitis, and pneumonia; (2) urinary tract; (3) brain with meningitis; (4) skin with VZV 
infection; (5) heart with endocarditis; (6) bone and joint infections; and (7) bacteremia [14, 43, 
47–51]. Bacterial infections are the most frequent etiological agents. However, invasive fungal 
infections (IFIs) caused by molds such as Aspergillus species and Fusarium species have been 
1 Patient-related factors:
• Female gender
• Old age
• Poor performance status and poor general condition
• Presence of comorbid medical conditions
• Hyperglycemia and uncontrolled diabetes mellitus
• Renal dysfunction/failure
• Increased serum ferritin level
2 Disease-related factors:
• Active disease
• Advanced disease; stage III according to international staging system
• Relapsed and refractory disease
• Immune dysfunction:
 ○ Suppression of cellular and humoral immunity including hypogammaglobulinemia
 ○ Low CD4+ cell count
 ○ Dysfunction of natural killer cells
3 Treatment-related factors:
• High-dose chemotherapy: melphalan, cyclophosphamide
• Novel therapies:
 ○ Immunomodulatory agents: thalidomide, lenalidomide, pomalidomide
 ○ Proteasome inhibitors: bortezomib, carfilzomib
 ○ Monoclonal antibodies: daratumumab, elotuzumab
• Neutropenia and lymphopenia
• Mucositis
• Presence of central venous catheters
• Corticosteroids: high dose or prolonged duration of therapy
• Autologous hematopoietic stem cell transplantation
• Allogeneic hematopoietic stem cell transplantation
Table 1. Risk factors for infectious complications in multiple myeloma.
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increasingly reported [50]. The incidence of infections in MM patients has bimodal peaks: 
bacterial infections dominate 4–6 and 70–72 months after the diagnosis, while viral infections 
dominate 7–9 and 52–54 months after the diagnosis of MM [13].
In patients with MM having active disease, the following types of infections are common: 
bacteremia, pneumonia, sinusitis, otitis, meningitis, and IFIs [14, 50]. In active disease, Gram-
negative bacterial (GNB) particularly encapsulated bacteria and fungi are common causes of 
infectious complications [14].
Patients with MM are at high risk of developing infections as infections in these patients have 
been reported to be 10 times more than that in healthy individuals. Also, the new novel thera-
pies make patients with MM at higher risk of infectious complications than myeloma patients 
treated with cytotoxic chemotherapy [52, 53]. Even, prior to the diagnosis of MM, there is an 
underlying immune disturbance, which may predispose to various infections such as VZV, 
sinusitis, cystitis, and bronchitis that may be encountered during the disease evolution [54].
4.1. Neutropenia and febrile neutropenia
Neutropenia is a hematologic adverse event of medications characterized by an absolute neu-
trophil count (ANC) lower than 1500 cells/mL [55]. Neutropenia is a well-recognized com-
plication of cytotoxic chemotherapy. Also, it develops in patients with MM receiving novel 
therapies or undergoing HSCT [55–57]. Prolonged and severe neutropenia increases the risk 
of febrile neutropenia (FN) and serious infections that may be life-threatening [57]. Persistent 
neutropenia causes not only delay in administration of chemotherapy or novel therapies, but 
also dose reductions in the next cycle of chemotherapy. Nevertheless, once the ANC reaches 
≥1000 cells/mL, scheduled treatment may be resumed [55].
FN is a serious effect of chemotherapy, and it has the following adverse consequences: delay in 
administration of scheduled therapies, costs of hospitalization, and increased risk of morbid-
ity and mortality in immunocompromised individuals [58]. Several studies have shown that 
the following risk factors for neutropenia and FN in patients with MM: (1) heavily pretreated 
disease and relapsed and refractory (R/R)-MM, (2) elderly patients with comorbid medical 
conditions, and (3) use of the following drugs particularly in combination with other agents 
such as lenalidomide, bendamustine, and the combination of bendamustine, bortezomib and 
dexamethasone [55, 58–60].
Management of patients with prolonged neutropenia and FN includes: (1) thorough physical 
evaluation for the site or source of infection, (2) taking enough cultures and septic screens, 
(3) administration of prophylactic and empirical antimicrobials, and (4) pre-emptive or pro-
phylactic administration of granulocyte-colony stimulating factor (G-CSF) in patients who are 
expected to have prolonged or severe neutropenia [58, 59]. However, the choice of empirical 
antibiotic therapy in patients with HMs having FN depends on the risk stratification of the indi-
vidual patient [61, 62]. In low-risk (LR) patients with FN, duration of neutropenia is <1 week 
and there are no comorbid medical conditions; while in high-risk (HR) patients with FN, the 
duration of neutropenia is >1 week and there are comorbid medical conditions [61, 62]. In case 
the patient is stratified as LR, oral antibiotics such as ciprofloxacin or levofloxacin are sufficient, 
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while if the patient belongs to the HR group, intravenous (IV) antibiotics may need to be admin-
istered. IV ceftazidime, piperacillin-tazobactam, or a carbapenem can be given as single agents 
or in combination with either vancomycin or an aminoglycoside [62–65]. However, the fact that 
there is a recent increase in the incidence of Gram-positive bacteria (GPB) cultured from neu-
tropenic patients with MM has to be taken into consideration [56]. Empirical antifungal therapy 
can be used in patients with persistent fever despite the use of broad-spectrum antibiotics [61, 
62, 66]. In addition, recombinant G-CSF is commonly used to reduce the incidence, duration, 
and severity of FN [57]. Studies have shown that the use of G-CSF as primary prophylaxis 
improves quality of life, is cost-effective as it reduces the: days of hospitalization, infectious 
complications, and incidence of chemotherapy interruptions [58, 59].
4.2. Bacterial and bloodstream infections in MM
Bloodstream infections (BSIs) are important causes of morbidity and mortality in patients 
with HMs, and they contribute to delayed administration of planned chemotherapy, increased 
length of hospitalization, and increased health care costs [29]. The risk factors for bacteremia 
or bacterial BSIs in patients with HMs include the primary disease, neutropenia induced by 
intensive chemotherapy, and mucositis due to the cytotoxic effects of chemotherapy on the 
cells of gastrointestinal tract [67, 68]. In recent years, there has been a shift in prevalence of the 
causative organisms for bacterial BSIs in patients with HMs from GPB to GNB. Also, there has 
been increasing frequency of antimicrobial resistance in GNB [69]. Therefore, in patients with 
HMs having FN, BSIs caused by GNB should initially be treated with non-carbapenem-based 
anti-pseudomonal therapy taking into consideration the antimicrobial stewardship [67].
In patients with MM undergoing autologous HSCT, mucositis and chemotherapy-induced 
neutropenia are risk factors for the development of bacteremia [67, 68]. In two retrospective 
studies on BSIs that included 421 patients with MM, the following results were obtained: (1) 
the independent risk factors for BSIs were: advanced stage of disease, poor performance sta-
tus, and receipt of autologous HSCT; (2) GPB, mainly Streptococcus pneumonia, were respon-
sible for the majority of BSIs during the induction phase of treatment while GNB, mainly 
Escherichia coli, were responsible for the majority of BSIs in progressive disease; (3) the highest 
incidence of BSIs was encountered during the first 3 months from the diagnosis and during 
disease progression; (4) admissions to the intensive care unit were required in 23% of patients 
with BSIs; and (5) mortality rates due to BSIs were 11.5% in patients with progressive disease 
and 50% in patients with newly diagnosed MM [29, 70].
Bacteremia may antedate the diagnosis of MM and may be related to the use of venous cath-
eters used during stem cell collection or autologous HSCT [71, 72]. Polymicrobial or multiple 
microbiologically confirmed infections are frequent and may cause serious consequences in 
recipients of HSCT [73]. Several studies have shown that the use of ciprofloxacin or levofloxa-
cin prophylaxis in patients with MM undergoing autologous HSCT is associated with signifi-
cant reduction in the incidence of FN, bacteremia, and pneumonia [68, 74, 75]. On the contrary, 
a randomized phase III study that included 212 MM patients undergoing induction therapy 
showed that the prophylactic use of antibiotics did not decrease the incidence of serious bac-
terial infections, thus obviating the need for the routine use of antibacterial prophylaxis in 
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patients with MM receiving induction therapy [76]. However, other studies have shown that 
the addition of doxycycline to ciprofloxacin and the sequential use of levofloxacin followed 
by ertapenem in patients with MM subjected to autologous HSCT reduce the frequency of 
FN episodes, bacteremia, and documented bacterial infections without increasing the rate of 
serious complications [77, 78].
4.3. Viral infections in MM
Reactivation of CMV after autologous HSCT performed for patients with MM is relatively 
common and is mainly encountered in patients receiving tandem rather than single HSCT; 
HD-melphalan conditioning therapy; and induction with combination therapy particularly 
bortezomib, thalidomide, and dexamethasone [79]. Also, reactivation of human herpes virus-6 
is relatively common following autologous HSCT and is usually associated with postengraft-
ment fever [80]. Several studies performed in patients with MM have shown that the risk fac-
tors for reactivation of VZV, HSV, and hepatitis-B virus (HBV) include (1) progressive disease, 
(2) treatment with proteasome inhibitors such as bortezomib, (3) treatment with immuno-
modulatory agents particularly lenalidomide, and (4) HSCT [81–87].
Viremia caused by CMV is common and is often associated with fever, while CMV disease 
with biopsy proven tissue infiltration is rare in patients with MM receiving autologous HSCT 
[79]. CMV surveillance should be considered in patients with MM subjected to autologous 
HSCT, particularly those receiving tandem transplants, HD-melphalan and combination 
therapies for induction [79]. Acyclovir of valacyclovir prophylaxis should be offered to HR 
patients including recipients of HSCT, patients with progressive disease, and patients treated 
with bortezomib or lenalidomide [81–87].
4.4. Fungal infections in MM
Candidemia and IFIs are major complications in patients with HMs who develop prolonged 
and severe neutropenia. Additionally, IFIs are difficult to diagnose in these severely immuno-
compromised patients [88–91]. In patients with MM prior to the introduction of novel therapies, 
IFIs were encountered in patients treated with traditional intensive cytotoxic chemotherapeutic 
regimens and mortality rates due to IFIs were reaching 60% [91]. In the era of novel therapies, 
IFIs are associated with mortality rate of approximately 44% and are mainly encountered in 
MM patients having: (1) progressive disease, (2) ≥ 3 lines of therapy administered, (3) received 
HSCT, particularly in the early post-transplant period, and (4) history of IFI treated [91–93].
Over the past two decades, the spectrum of Candida species infections has shifted to non-albicans 
species, which frequently exhibit decreased susceptibility to fluconazole [89]. Empirical anti-
fungal agents are recommended in patients with HMs having neutropenia and persistent or 
recurrent fever despite appropriate antibiotic therapy [88]. In patients with candidemia or inva-
sive infection caused by Candida species, echinocandins such as caspofungin, liposomal ampho-
tericin-B, and voriconazole are the treatments of choice, while voriconazole is the treatment of 
choice for IFIs caused by Aspergillus species [67, 89, 90, 92]. However, fluconazole is still the most 
common antifungal agent used for prophylaxis in HR patients and in recipients of HSCT [91, 92].
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4.5. Tuberculosis in patients with MM
Tuberculosis (TB) is the most common cause of death from a single infectious agent world-
wide [94]. In patients with HMs and in recipients of HSCT living in geographic locations 
that are endemic for TB, these infections are uncommon, but they cause significant morbid-
ity and mortality [95, 96]. Early diagnosis, prompt administration of anti-TB chemotherapy, 
and adherence to treatment schedules are associated with successful outcome, while delayed 
management, drug resistance, and presence of disseminated infection are associated with 
poor prognosis and high mortality rates [95, 96].
The incidence of TB infection is higher in patients with MM than in the general population. 
Also, patients with MM have higher risk of mortality compared to MM patients without 
TB [97]. The risk factors for TB infection in patients with MM include: (1) the disease itself 
with its associated immunological abnormalities that include hypogammaglobulinemia 
as well as abnormal T cell-mediated and humoral immunities, (2) treatment of MM that 
includes corticosteroids, cytotoxic chemotherapy, and novel therapies such as bortezomib, 
(3) old age, (4) alcohol use disorder, (5) poor socioeconomic conditions, (6) HSCT, and 
(7) presence of comorbid medical conditions such as diabetes mellitus and malnutrition 
[94–104].
TB infections in patients with MM can be primary infections or reactivation of old or latent 
TB infections [94, 100, 101]. Reactivation of TB may by induced by (1) HD corticosteroids, (2) 
cytotoxic chemotherapy, (3) administration of novel therapies, and (4) autologous as well as 
allogeneic HSCT [95, 104]. In patients with MM receiving bortezomib-containing regimens, 
TB infections are uncommon [94]. In a retrospective analysis of 115 patients with MM treated 
with bortezomib-based therapy: TB infection was diagnosed in 7% of cases, bortezomib 
therapy was interrupted in 50% of the patients treated for TB and this affected outcome of 
patients significantly, but none of the patients died because of uncontrolled TB infection. In 
these patients, early diagnosis and prompt anti-TB treatment were essential to avoid further 
worsening of the outcome [94].
TB infections may be diagnosed at the time of diagnosis of MM or may evolve during or 
after treatment of MM [98–100, 105]. In patients with MM, TB infections have been reported 
to involve: (1) lungs with pulmonary infiltration, lung nodules, and bronchiectasis; (2) spine 
causing paraspinal masses and spinal cord compression; and (3) meninges with TB menin-
gitis [98–100, 105]. However, spinal TB is the most serious form of TB infections [100]. TB 
infections in MM patients may coexist with infections caused by other microorganisms such 
as Staphylococcus aureus [99].
TB infections are 10–40 times more common in recipients of HSCT than in the general 
population. Also, approximately 80% of Mycobacterium tuberculosis infections encountered in 
recipients of HSCT have been reported in allograft recipients [96, 103, 104]. Patients with MM 
having latent TB or history of treated TB infection planned for novel therapies or subjected 
to cytotoxic chemotherapy or HSCT should receive isoniazid prophylaxis to prevent reactiva-
tion of their TB infections [95, 96, 101].
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4.6. Bone and joint infections in MM
Bone and joint infections are uncommon in patients with MM. These infections manifest as: 
osteomyelitis, septic arthritis, and prosthetic joint infections [51, 106]. The pathogens encoun-
tered are similar to those cultured in patients without myeloma, although GPB predominate 
and polymicrobial infections occur less frequently [51]. In patients with MM treated with 
radiotherapy or IV bisphosphonates, there is a risk of developing osteonecrosis of the jaw 
[106, 107]. Patients with osteonecrosis of the jaw are at risk for developing infections and often 
require long-term antimicrobial therapy [108]. Having history of jaw osteonecrosis is not a con-
traindication for HSCT as the outcome of these patients is not worsened by HSCT itself [108].
5. Infections associated with use of novel agents
Infections represent a significant cause of morbidity and a leading cause of death in patients 
with MM [13, 53]. The novel therapies that have been introduced over the past decade have 
improved the survival of patients with MM [53, 109]. Consequently, management of disease 
complications such as infections has become an important issue as patients with MM survive 
longer [53]. The pattern of infection and the risk factors for infection in MM patients have 
shifted due to the evolution of new therapies and the widespread use of HSCT [13, 43].
Several studies have shown that the use of immunomodulatory agents such as thalidomide 
and lenalidomide and proteasome inhibitors such as bortezomib, particularly if they are used 
in drug combinations that include corticosteroids in the treatment of MM at any stage, induc-
tion, relapse, or maintenance, are associated with increased risk of infectious complications, 
thus making the use of antimicrobial prophylaxis with fluoroquinolones, acyclovir, cotri-
moxazole, and fluconazole essential [13, 52, 110, 111]. Also, in a meta-analysis that included 
13 clinical trials, with 2402 patients participating, the use of daratumumab and elotuzumab in 
the treatment of R/R-MM was associated with myelosuppression in the form of neutropenia 
and lymphopenia and subsequent risk of infectious complications such as pneumonia [109].
5.1. Infections associated with use of thalidomide
Thalidomide is not significantly myelotoxic, so the risk of infection in patients with MM receiv-
ing thalidomide alone is very low [14]. However, severe infections have been encountered 
once thalidomide is used in combination with other drugs in the treatment of MM. Therefore, 
antibiotic prophylaxis is needed once thalidomide is used in combination with other drugs 
such as dexamethasone [112].
5.2. Infections associated with use of lenalidomide
Lenalidomide has more potent costimulatory effects on CD4+ and CD8+ cells than thalido-
mide, and it causes neutropenia as part of myelosuppression, which is highest during the 
initial cycles of therapy and then it decreases thereafter [14, 31, 113].
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Serious infections and even deaths have been encountered with the use of lenalidomide [31]. 
Several studies have shown the following results once lenalidomide is combined with dexa-
methasone: (1) various infections are prone to occur, and (2) these infectious complications 
may be severe to the extent that the patients need hospitalization to receive G-CSF and IV 
antimicrobial therapy, (3) respiratory tract infections are common, and (4) viral infections 
such as VZV may be encountered requiring treatment as well as prophylaxis with acyclovir 
[14, 82, 113–116].
5.3. Infections associated with use of pomalidomide
Pomalidomide causes neutropenia [44, 116, 117]. When combined with dexamethasone in the 
treatment of patients with MM, severe infections may develop and pneumonia is a commonly 
encountered infection [44, 116, 117].
Infection is the second most common cause of death, after disease progression, in MM patients 
treated with pomalidomide [44]. Patient receiving pomalidomide therapy may have interrup-
tion of their scheduled treatment in case of severe infection and may need: G-CSF administra-
tion, antimicrobial prophylaxis with quinolones and cotrimoxazole, and even revaccination 
[44, 116, 117].
5.4. Infections associated with use of bortezomib
Bortezomib causes decreased lymphocytic count and imbalance in T-lymphocyte subsets due 
to its potent immunosuppressive effect on T cells [14, 118–120]. Several studies have shown 
that the use of bortezomib in the treatment of patients with MM is associated with develop-
ment of the following infectious complications: (1) viral infections such as HSV and VZV 
infections mainly in patients with IgG type of myeloma, (2) fungal infections, (3) bacterial 
infections, mainly in IgG type of MM, and (4) TB reactivation, which is more pronounced 
in patients receiving other drugs, such as thalidomide and cyclophosphamide, in combina-
tion with bortezomib [14, 118, 119, 121]. However, one study found that Epstein–Barr virus 
(EBV)-positive B-cells were more susceptible to killing by bortezomib. Hence, the drug could 
represent a novel strategy for the treatment of certain EBV-associated lymphomas [122].
5.5. Infections associated with use of carfilzomib
Carfilzomib causes BM suppression that includes lymphopenia [123, 124]. The use of carfil-
zomib in the treatment of MM has been associated with the following infections: bacterial 
pneumonia, viral respiratory tract infections, and bacterial sepsis [123, 124].
5.6. Infections associated with use of daratumumab
Daratumumab has the following effects: neutropenia, lymphopenia, hyperglycemia, and 
decrease in natural killer cells, which play a major role in the immune clearance of virally infected 
cells [125, 126]. The use of daratumumab in the treatment of MM patients is associated with the 
following infections: nasopharyngitis, pneumonia, and viral infections such as VZV [125–128].
Update on Multiple Myeloma190
5.7. Infections associated with use of elotuzumab
Elotuzumab can cause neutropenia, lymphopenia, and hyperglycemia [129–132]. Several 
studies have shown that its use in the treatment of patients with MM is associated with the 
following infections: pneumonia, sepsis, and even leishmaniasis [129–131, 133].
5.8. Infections related to corticosteroids and bisphosphonates
Corticosteroids predispose to infectious complications by causing immune suppression 
and hyperglycemia [13, 14, 39]. The following infections have been reported in patients 
with MM receiving corticosteroid therapy: (1) Candida albicans and non-albicans Candida; (2) 
Mycobacteriaceae; (3) viruses such as HSV, VZV, CMV, and respiratory viruses; (4) encapsu-
lated bacteria such as Staphylococcus aureus, Streptococcus pneumonia, Pseudomonas aeruginosa, 
and Enterobacter aerogenes; and (5) PJP [13, 14, 39]. The use of bisphosphonates in patients with 
MM is associated with osteomyelitis and osteonecrosis of the jaw [14].
6. Infections related to HSCT in MM
Prior to the era of novel therapies for MM, studies in patients with HMs receiving autologous 
HSCT showed that there was no significant difference in incidence, type of infection, and 
clinical course of infection between patients with MM and patients with other HMs [134, 135]. 
However, a recent study showed that in-hospital mortality in patients with MM receiving 
autologous HSCT was approximately 1.5% and that there was no significant difference in 
mortality between elderly individuals and young patients [136]. Nevertheless, elderly patients 
were more likely to develop complications such as pneumonia, septic shock, acute respiratory 
failure needing endotracheal intubation, acute renal failure, and cardiac arrhythmias [136].
In patients with MM having dialysis-dependent renal failure are at higher risk of FN and 
infectious complications such as septic shock compared to patients without renal failure 
[137]. Patients with MM subjected to autologous HSCT are at higher risk of developing bacte-
rial meningitis, which is associated with high rates of mortality and morbidity [138]. MM 
patients having MBL2 (mannan-binding lectin, which is part of the innate immune system 
that protects against severe infections during autologous HSCT) polymorphism are at risk of 
severe infections particularly after receiving HD-melphalan and autologous HSCT [139]. In 
addition to the administration of prophylactic antimicrobials in patients with HR-MM and 
in recipients of HSCT, strategies to reduce the incidence of infectious complications include 
administration of IV immunoglobulins and vaccination despite the likelihood of vaccination 
failure [140, 141].
During stem cell mobilization, infections related to central venous catheters are likely to occur 
with predominance of GPB [142]. Conditioning therapy with HD-melphalan causes mucositis 
and myelosuppression with neutropenia [14]. The use of melphalan is associated with colitis, 
pneumonia, and bacteremia, and these infections are usually caused by the following encap-
sulated bacteria, Candida species and Aspergillus species [14].
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During the post-transplant period, organisms such as Clostridium difficile, CMV, HSV, VZV, 
PJP, and other opportunistic organisms dominate [13, 14, 141]. The sites of infection during 
this period are gastrointestinal, respiratory, and urinary tracts [13, 14]. In the pre-engraft-
ment period of time: bacteremia, pneumonia, cellulitis, and gastrointestinal infections with 
Clostridium difficile occur, while VZV, CMV, Clostridium difficile, and PJP with gastrointes-
tinal tract, lung and skin infections dominate in the post-engraftment period of time [14]. 
Bacteremia in recipients of autologous HSCT is associated with previous bortezomib therapy 
and elevated beta-2 microglobulin level [141]. Recently, a significant increase in the incidence 
of infections caused by multidrug resistant organisms (MDROs) has been encountered [143]. 
Also, colonization with MDROs in recipients of autologous HSCT has negative impact on 
OS due to the profound immunosuppression caused by the HMs and their treatments [143].
Reactivation of HBV is a well-recognized complication in patients with chronic HBV infec-
tion undergoing cytotoxic chemotherapy or immunosuppressive treatment [144]. In patients 
undergoing autologous HSCT, reverse seroconversion of HBV is not a rare complication and 
this poses concerns about possible complications in such severely immunocompromised indi-
viduals [144]. There is an extremely low incidence of PJP in recipients of autologous HSCT; 
thus, routine PJP prophylaxis should not be offered routinely to this population group. 
However, patients who require systemic corticosteroid therapy in the post-transplant period 
are candidates for PJP prophylaxis [145].
7. Conclusions and future directions
The introduction of the novel agents in the treatment of patients with MM has led to unprec-
edented improvements in survival rates. However, these novel therapies have their own 
toxicities that include BM suppression and various infectious complications. These infections 
include bacterial, viral, fungal, mycobacterial, and parasitic infections. Also, they can be local 
or disseminated and can affect the bloodstream and may invade internal organs, thus causing 
life-threatening illnesses.
As these infectious complications vary according to the stage of the disease and the specific 
agents used, prospective and multicentric studies are needed to explore the real extent of 
these infections in order to establish guidelines for the use of antimicrobial agents in the pro-
phylaxis as well as the treatment of the various infections that can be encountered.
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